Semon Dominique 4
4 · SUNESIS PHARMACEUTICALS INC · Filed May 4, 2010
Insider Transaction Report
Form 4
Semon Dominique
10% Owner
Transactions
- Exercise of In-Money
Common Stock
2010-04-30$0.22/sh+1,699.14$374→ 4,303,637 total(indirect: See Footnotes) - Sale
Common Stock
2010-04-30$0.98/sh−382,542$373,820→ 3,921,095 total(indirect: See Footnotes) - Exercise of In-Money
Warrants
2010-04-30$0.13/sh−1,699,140$212,393→ 0 total(indirect: See Footnotes)Exercise: $0.22From: 2010-10-27Exp: 2016-10-31→ Common Stock (1,699,140 underlying)
Footnotes (4)
- [F1]On April 30, 2010 Nexus Gemini L.P. ("Gemini") and Merlin Nexus III, L.P. ("Nexus III") exercised 699,640 and 999,500 Warrants, respectively, and in exchange acquired 699,640 and 999,500 shares of Common Stock, respectively, at an exercise price of $0.22.
- [F2]The Reporting Person is the managing member of Nexus Gemini Advisors, LLC and Merlin Biomed Private Equity Advisors, LLC, the investment advisors to Gemini, Merlin Nexus II, L.P. ("Nexus II"), and Nexus III, collectively ("the Funds"). The Funds own direct interests in the reported securities.
- [F3]The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F4]On April 30, 2010 Gemini and Nexus III sold 157,516 and 225,026 shares of Common Stock, respectively.